Article info

Original research
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma

Authors

  1. Correspondence to Dr Yousef Zakharia; yousef-zakharia{at}uiowa.edu
View Full Text

Citation

Zakharia Y, McWilliams RR, Rixe O, et al
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma

Publication history

  • Accepted March 16, 2021
  • First published June 11, 2021.
Online issue publication 
June 11, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.